2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.29 Characteristics of Osimertinib Non-Responders vs Responders in EGFR Mutated Lung Cancer

Pdf Summary

The document presents a retrospective study examining the characteristics and outcomes of patients with EGFR-mutated non-small cell lung cancer (NSCLC), specifically focusing on those who respond and do not respond to the treatment with Osimertinib. It provides detailed data on patient characteristics, including tumor burden, lymph node involvement, CNS disease presence, and the timing and effect of radiation treatment.<br /><br />The study involved 125 patients across two EGFR mutations (Exon 19 and L858R) and distinguished between responders and non-responders to Osimertinib, an EGFR inhibitor known for improving overall survival (OS) and progression-free survival (PFS) based on previous FLAURA trials. It included patients starting first-line Osimertinib but excluded those who discontinued due to side effects or could not tolerate the full 80mg dose.<br /><br />The key findings indicate that patients with oligometastatic disease, limited or no hilar/mediastinal lymph node involvement, and those receiving late radiation exhibited improved PFS and OS. Moreover, CNS disease at diagnosis or early radiation treatment to the brain did not show a statistically significant impact on lower PFS and OS.<br /><br />Data tables and Kaplan-Meier curves in the document provide detailed analysis on PFS concerning tumor burden, lymph node status, radiation timing, and brain radiation involvement. The study's result section reflects on the measured PFS and hazard ratios, indicating varying outcomes based on different clinical interventions and patient characteristics. The inclusion of statistical data offers insights into how specific interventions might benefit particular patient groups.<br /><br />This study underscores the importance of personalized treatment strategies in managing EGFR-mutated NSCLC, emphasizing the role of metastasis extent and radiation timing on patient outcomes.

Asset Subtitle

Amanda Reyes

Meta Tag

Speaker Amanda Reyes

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR-mutated NSCLC

Osimertinib

tumor burden

lymph node involvement

CNS disease

radiation treatment

progression-free survival

oligometastatic disease

personalized treatment

Kaplan-Meier curves